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Abstract
Objective—Increasing data support a role for antibody-dependent cellular cytotoxicity (ADCC)
in controlling HIV-1 infection. We recently isolated a naturally-occurring dimeric form of the
anti-HIV-1 antibody 2G12 and found it to be significantly more potent than 2G12 monomer in
neutralizing primary virus strains. However, given the unusual structure of dimeric 2G12 with two
Fc regions, it was not clear whether 2G12 dimer could bind to the CD16 Fc receptor on ADCC
effector cells or trigger ADCC. Here we compared the in vitro ADCC activities of 2G12 monomer
and dimer and investigated the effects of including ADCC-enhancing mutations in both forms of
2G12.
Methods—An in vitro ADCC assay using target cells stably expressing gp160 was developed to
evaluate the activities of 2G12 monomer and dimer with and without ADCC-enhancing mutations
that increase the CD16-binding affinity of the 2G12 Fc region.
Results—Both 2G12 monomer and 2G12 dimer elicited ADCC, although the dimer showed
increased potency (lower half-maximal concentration [EC50]) in triggering ADCC, thus
confirming its ability to bind CD16 and trigger ADCC. The ADCC-enhancing mutations improved
the ADCC activity of 2G12 monomer more than 2G12 dimer such that their EC50 values were
nearly equal. However, no increase in non-specific ADCC activity was observed using 2G12 IgGs
with these mutations.
Conclusion—Given the likelihood that ADCC plays a role in protecting against initial infection
and/or controlling chronic infection, these data suggest 2G12 dimers and/or addition of ADCC-
enhancing mutations could augment the prophylactic and/or therapeutic potential of 2G12.
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Introduction
Antibodies can prevent or contribute to the elimination of a viral infection by multiple
mechanisms including neutralization (i.e., binding directly to virus particles to prevent entry
into target cells), antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis of
infected cells upon opsonization, and activation of the classical pathway of complement [1].
ADCC is initiated by Fc receptors on innate immune cells recognizing the Fc regions of
clustered IgG1 and IgG3 antibodies bound to the surface of infected cells, resulting in a
cytolytic response against targeted cells [2]. Multiple subpopulations of peripheral blood
mononuclear cells (PBMCs) are capable of ADCC [2, 3], but particular attention has been
given to ADCC activity triggered by cross-linking CD16 (FcγRIIIa) on the surfaces of
natural killer (NK) cells [4, 5], which are the largest subset of peripheral leukocytes after T
and B cells [6].
Considerable evidence supports a role for ADCC activity in the control of human
immunodeficiency virus type 1 (HIV-1) infection (reviewed in [1, 7]). HIV-infected
individuals whose sera can trigger ADCC in vitro have lower viral titers and higher CD4+ T
cell counts than infected individuals whose sera are less active in ADCC [8, 9]. ADCC-
inducing antibodies arise earlier and in higher titers than neutralizing antibodies during the
acute phase of HIV-1 infection [10–14]. The emergence of NK cell-dependent viral
inhibition by IgG from HIV-1-infected donors is also correlated with reductions in viral load
during the acute phase of infection [10], and the loss of CD16 expression on NK cells
isolated during the chronic phase of infection is associated with increased viral load [15].
Lastly, when the ability to trigger ADCC through CD16 binding was eliminated for the
broadly-neutralizing anti-HIV antibody b12, which targets the CD4 binding site of gp120,
the mutant antibody could no longer protect macaques from viral challenge at dosages that
were sufficient for protection by wild-type b12 [16]. Thus, while the ability to neutralize
HIV-1 in vitro has generally received the greatest attention when judging the performance of
anti-HIV antibodies [1], it is becoming increasingly clear that ADCC-mediated mechanisms
of HIV-1 control deserve equally careful scrutiny.
2G12 is a potent neutralizing anti-HIV-1 IgG, which protects rhesus macaques against viral
challenge [17, 18] and can trigger ADCC in an in vitro assay [19, 20]. 2G12 binds to a
constellation of high mannose carbohydrates on the gp120 portion of the HIV-1 envelope
spike using an unusual 3D domain swapped structure [21]. Typical IgGs contain two heavy
chains and two light chains, which form two Fabs from the pairing of the light chain variable
and constant domains (VL and CL) with the VH and CH1 domains of the heavy chain. In
most IgGs, the Fabs are free to rotate independently about the hinge region that connects
them to the Fc region, resulting in two antigen binding sites separated by distances ranging
from 10 to 15 nm. However, domain-swapped monomeric IgG 2G12 has two VH domains
that have exchanged their VL domain binding partners [21]. As a result, the two
carbohydrate binding sites created by the VH-VL domains of the Fabs are separated by a
fixed distance of ~3.5 nm, and two additional carbohydrate binding sites are created at the
interface of the two VH domains [21].
We recently reported that expression of 2G12 in mammalian cells results in a mixture of
2G12 monomer and a higher molecular weight oligomer that was characterized as a 2G12
dimer containing four heavy chains and four light chains, which combine to form four Fabs
and two Fc regions [22]. The dimeric form of 2G12 exhibited 50- to 80-fold increased
neutralization potency against a panel of clade A and B HIV-1 strains relative to the
monomer [22]. We presented a model for how inter-domain swapping between two 2G12
monomers could create a 2G12 dimer [22], but the precise arrangement of the two Fc
regions in dimeric 2G12 and the accessibility of its FcγR binding sites are unknown.
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Here we investigated whether 2G12 dimer could elicit ADCC and whether the enhanced
neutralization potency of dimeric versus monomeric 2G12 also extends to the FcγR-
dependent function of ADCC. Previous results investigating ADCC induction by 2G12
monomers used an in vitro assay involving T cells coated with monomeric gp120 bound to
CD4 as targets [19, 20]. Given that epitopes for monomeric and/or dimeric 2G12 might not
be accurately preserved when using soluble monomeric gp120 bound to CD4, we developed
an in vitro ADCC assay using a previously-described cell line stably transfected to express
HXB2 gp160 [23] as target cells. We found that both monomeric and dimeric 2G12 elicited
efficient ADCC responses with dimeric 2G12 being 6.8-fold more potent than monomeric
2G12. We also introduced mutations into the 2G12 Fc region that enhance its affinity for
CD16 [24]. These mutations increased ADCC potency to a greater extent for 2G12
monomer as compared to 2G12 dimer, reducing their difference in potency to 3.3-fold.
Given previous evidence for a significant protective effect by 2G12 in both human and
primate studies [17, 25], these results suggest that incorporating ADCC-enhancing
mutations into 2G12 and the use of dimeric 2G12 are worth consideration in the context of
passively administered immunotherapy or gene therapy.
Materials and Methods
Protein expression and purification
IgG 2G12 (2G12WT) was expressed transiently in suspension HEK 293-6E cells and
purified from transfected cell supernatants using protein A chromatography as described
[22]. Monomeric and dimeric versions of 2G12WT in neutralized protein A eluates were
separated using size exclusion chromatography by two or more passages over a Superdex
200 16/60 or 10/30 column (GE Healthcare, Piscataway, New Jersey, USA) [22]. Mutations
that enhance the affinity of IgG (Ser239 to Asp and Ile332 to Glu) for CD16 and increase
ADCC potency in the presence of effector cells [24] were introduced into the Fc region of
the 2G12 heavy chain gene using the QuikChange mutagenesis kit (Agilent Technologies,
La Jolla, California, USA) to create 2G12S239D/I332E. Monomeric and dimeric forms of
2G12S239D/I332E were expressed and purified as described for 2G12WT. Purified rituximab
(an IgG antibody against CD20 used as a negative control) was the gift of Dr. Sanjeev
Nandakumaran (Kaiser Permanente Southern California Medical Group). All antibodies
were of the human IgG1 subclass.
ADCC assay
Target cells were a Chinese hamster ovary cell line expressing the full-length envelope spike
from the clade B strain HXB2 (CHO-WT; here referred to as CHO-gp160) and glutamine
synthetase was used for selection and amplification [26], which was obtained through the
AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: CHO-
SEC from Dr. Carol Weiss and Dr. Judith White. Another CHO cell line (CHO-HFE) [27],
also generated using the glutamine synthetase system, was used as a negative control target
cell line. Both cell lines were cultured in the absence of glutamine as previously described
[23, 28].
Human peripheral blood mononuclear cells (PBMCs) were purified from a lymphophoresis
pack obtained from a single healthy volunteer (Hemacare, Van Nuys, California, USA) by
standard Ficoll-Hypaque gradient centrifugation (Ficoll-Paque PLUS User Manual, cat#
17-1440-02, GE Healthcare). Cells were immediately frozen at 100 × 106 cells/mL in 80%
heat-inactivated fetal bovine serum (FBS) supplemented with 20% DMSO. Approximately
24 to 48 hours prior to use, cells were thawed and cultured in RPMI-complete media
(RPMI1640 medium [Invitrogen, Carlsbad, California, USA] supplemented with 10% FBS,
2 mM glutamine [Invitrogen], 5000 U/mL Penicillin-Streptomycin (pen-strep) [Invitrogen],
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1% MEM non-essential amino acids [Invitrogen], and 1% sodium pyruvate [Invitrogen]) at a
density of 1.3×107 cells/mL in an upright 75 cm2 flask to deplete adherent cells. ADCC
assays were conducted by measuring radioactivity released from target cells metabolically-
labeled with 35S after incubation with IgG and purified PBMCs.
Target cells (CHO-gp160 or CHO-HFE) seeded into 96-well flat-bottom plates at 10,000
cells per well were labeled for 24 hours in cysteine, methionine and glutamine-free DMEM
containing 250 µCi/mL 35S EasyTag Express Protein Labeling Mix [Perkin Elmer,
Waltham, Massachusetts, USA] and supplemented with 10% dialyzed, heat inactivated FBS,
200 µM methionine sulfoximine [Sigma-Aldrich, St. Louis, Missouri, USA], 3.7% NaHCO3
[Sigma-Aldrich], 5000 U/mL pen-strep [Invitrogen], 1% MEM non-essential amino acids
[Invitrogen], 1% sodium pyruvate [Invitrogen], 0.007% cytidine, uridine, guanosine, and
adenosine [Sigma-Aldrich], 0.006% asparagine and glutamate [Sigma-Aldrich]. Cells were
washed gently five times in PBS followed by reconstitution in RPMI-complete media and
then incubated on ice for 15 minutes. Antibody reagents were tested for ADCC activity in
triplicate at ten concentrations of a three-fold dilution series, starting with 150 µg/mL and
16.7 µg/mL, respectively, for monomeric and dimeric IgG species. PBMCs were added at an
effector to target cell ratio of 50:1 and incubated at 37°C for 4 hours. Once terminated, 50
µL of reaction supernatant was added to 150 µL Microscint 40 scintillation fluid
[PerkinElmer] and incubated for 16–18 hours in the dark at room temperature in
Optiplate-96 microplates [PerkinElmer] followed by liquid scintillation counting using a
MicroBeta TriLux scintillation counter [PerkinElmer]. In some experiments, cells were
labeled in batch in a 6-well plate at 500,000 cells per well and harvested with 5 mM EDTA
after 24 hours. After washing five times in PBS, cells were reconstituted with RPMI-
complete media into a 96-well round-bottom plate at 10,000 cells per well prior to
incubation with IgG and PBMCs. No significant differences in EC50 values were observed
between the two approaches.
Rituximab (150 µg/mL) was tested in parallel as an isotype control for non-specific lysis
against CHO-gp160 and CHO-HFE with and without PBMCs. The level of spontaneous 35S
release was determined by incubating target cells in RPMI-complete media alone, while the
levels of non-specific PBMC-associated 35S release and non-antibody-associated 35S release
were respectively obtained by incubating target cells with PBMCs or antibody alone for the
duration of the assay. Maximal 35S release levels were obtained by incubating target cells in
a final concentration of 750 mM NaOH 15 minutes prior to the termination of the ADCC
assay. Percentage maximal lysis was determined as follows: (35S release with antibody and
PBMC – 35S release with PBMC)/(maximal 35S release – 35S release with PBMC) × 100%.
Curves were fit using Prism version 4.0a (Graphpad Software, San Diego, California, USA)
to the equation L=N+(M−N)/{1+10[(LogEC50-X)*H]} where L is percentage lysis, M is the
maximal percentage lysis, N is the minimal percentage lysis, X is the Log of the
concentration of reagent being tested, and H is the Hill coefficient. We observed decreasing
levels of maximal lysis at concentrations greater than 50 µg/mL and 5.5 µg/mL for monomer
and dimer, respectively. This effect has been observed in ADCC studies unrelated to HIV
and is likely attributable to CD16 saturation by IgG not bound to target cells (J. Vielmetter,
personal communication); thus, these points were omitted from the curve fitting. Variations
in lysis maxima were observed in some experiments; however, variation in EC50 values
between replicates for any particular reagent remained low regardless of the amount of
maximal lysis.
In vitro neutralization assay
Pseudovirus neutralization assays were used to compare the neutralization potencies of
monomeric and dimeric forms of 2G12WT and 2G12S239D/I332E against HXB2
pseudoviruses. The assay, which measures the reduction in luciferase reporter gene
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expression in the presence of a potential inhibitor following a single round of pseudovirus
infection in TZM-bl cells [29, 30], was conducted using minor modifications as described
[31, 32]. Neutralization data were fit by non-linear regression analysis using Prism version
4.0a (Graphpad Software) and IC50 values were derived as described [31]. Tests of
statistical significance for the neutralization and ADCC assays were done using the two-
tailed Student’s t-test.
Results
Development of an ADCC assay using target cells expressing HIV-1 spike trimers
Multiple conserved N-linked glycans on the surface of gp120 have been identified that
contribute to the ability of 2G12 to bind to and neutralize HIV [20, 33, 34]. In particular,
structure-based analysis of mutagenesis data was used to identify several glycosylation sites
near the coreceptor binding site as being particularly critical components of the 2G12
epitope [34], and their elimination has been linked to escape from 2G12 in vivo [17, 35].
However, questions still remain with regard to the nature of 2G12 binding that could
undermine the previously-described method of using CD4+ cells coated with monomeric
gp120 as targets for ADCC [19, 20]. For example, the epitope(s) of 2G12 monomers and/or
dimers may span between gp120 subunits in a trimer. In addition, the presentation and
accessibility of FcγR-binding sites on 2G12 may differ when bound to a native trimeric
spike versus monomeric gp120 bound to CD4, and multiple binding orientations may exist
for monomeric and/or dimeric 2G12 on an intact trimer. Lastly, effects on ADCC potency
arising from the potential for multiple 2G12 antibodies to be bound to a single trimeric spike
would not be accurately replicated when using monomeric gp120. For these reasons, we
developed an ADCC assay using target cells previously shown to stably express trimeric
gp160 [23]. In addition to resolving the concerns outlined above, gp160-expressing target
cells offer additional advantages over cells coated with monomeric gp120 in that they can be
used to test the abilities of antibodies to trigger ADCC for epitopes that overlap the CD4
binding site of gp120, target the gp41 domain, and/or require a non-CD4 bound
conformation of gp120.
Conditions for the ADCC assay included a 15-minute pre-incubation period of antibody
with target cells on ice followed by the addition of human PBMCs at an effector-to-target
cell ratio of 50:1 and incubation for 4 hours at 37 °C. Low background lysis was observed
with the addition of a monoclonal anti-CD20 isotype control antibody, rituximab, to either
the CHO-HFE control or the CHO-gp160 cells and for all 2G12 antibodies against the CHO-
HFE cells (Fig. 1A), indicating that 2G12 is specific for gp120 despite its anti-carbohydrate
reactivity. The lack of ADCC activity by 2G12 against the control target cells is consistent
with a previous study that observed no significant lysis of CD4+ T cells in the presence of
2G12 and human PBMCs [20]. Maximal lysis against CHO-gp160 target cells was variable
between independent replicates for all of the reagents tested. However, the difference
between the average maximal lysis for any two reagents was not statistically significant (p >
0.05 for all pairwise combinations).
IgG 2G12 elicits more potent ADCC as a dimer than monomer
We recently described isolation of 2G12 monomers and dimers that do not detectably
interconvert and reported that purified dimeric 2G12 was an average of 50- to 80-fold more
potent than monomeric 2G12 in the neutralization of pseudotyped primary virus isolates
from clades A and B [22]. Here we confirmed the higher neutralization potency of 2G12WT
dimer versus 2G12WT monomer against the HXB2 HIV-1 strain (Fig. 1B) in order to make
comparisons with the HXB2-expressing target cells used in ADCC assays (CHO-gp160
cells). The HXB2 strain is unusually sensitive to neutralization by 2G12 monomer [22];
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thus, the increase in potency for 2G12 dimer as compared to the monomer was less than
observed in comparisons using less-sensitive primary virus isolates [22].
To investigate whether the enhanced neutralization potency of dimeric 2G12WT over
monomeric 2G12WT also extended to the ability to elicit ADCC, we compared their abilities
to trigger ADCC in vitro. We found that both monomeric and dimeric 2G12WT elicited
efficient ADCC responses with half-maximal effective concentration (EC50) values of 2.3 ±
0.8 and 0.34 ± 0.22 µg/mL, respectively (Table 1, Fig. 1C, D). Thus, dimeric 2G12WT
exhibited an average 6.8-fold increased potency as compared to monomeric 2G12WT (p <
0.001).
Fc mutations increase the ADCC potency of both monomeric and dimeric 2G12
Although the increased potency of dimeric versus monomeric 2G12WT observed in the
neutralization assay also extended to ADCC activity, the absolute values for the potencies of
both forms were 5- to 8-fold weaker in the ADCC assay, such that the average
concentrations at which half maximal neutralization was achieved for 2G12WT monomer
and dimer were 0.42 µg/mL and 0.044 µg/mL, respectively, versus average concentrations at
which half maximal lysis by ADCC was achieved for monomer and dimer, which were 2.3
µg/mL and 0.34 µg/mL, respectively. The higher concentrations of 2G12WT required for
ADCC as compared to concentrations required for neutralization could result from the low
affinity of IgG Fc regions for CD16 [24, 38].
To investigate the effects of increasing the affinity for CD16, we introduced a double
mutation to the Fc of 2G12 (S239D and I332E) that was previously shown to enhance the
affinity of IgG for CD16 and increase ADCC potency [24]. The mutant protein,
2G12S239D/I332E, was expressed and monomeric and dimeric forms were purified. The
mutations introduced to the 2G12 Fc region did not adversely affect the neutralization
potencies of either the monomeric or dimeric proteins: The IC50 values for 2G12S239D/I332E
monomer and dimer were 0.14 µg/ml and 0.031 µg/ml, respectively, as compared with
average IC50 values for 2G12WT monomer and dimer of 0.42 ± 0.11 µg/ml and 0.044 ±
0.013 µg/ml, respectively (Table 1). When evaluated in the ADCC assay, the ADCC-
enhancing mutations did not result in increased background activity against the CHO-HFE
control target cells (Fig. 1A), but we observed increased ADCC potency for both
2G12S239D/I332E monomer and 2G12S239D/I332E dimer against the target cells, yielding EC50
values of 0.17 ± 0.15 and 0.051 ± 0.035 µg/mL, respectively (Table 1, Fig. 1C, D). While
the increase in potency for the 2G12S239D/I332E monomer versus the 2G12WT monomer was
statistically significant (p < 0.001), the difference in potency between the two dimeric forms
was not statistically significant (p = 0.07). These results suggest that 2G12S239D/I332E and
2G12WT dimers bind CD16 with similar affinities, likely because avidity effects arising
from the presence of two Fc regions would limit the potential affinity enhancement of the Fc
mutations.
Discussion
Here we compared the abilities of monomeric 2G12 and a recently described naturally-
occurring dimeric form of 2G12 [22] to trigger ADCC by human PBMCs against target cells
stably expressing gp160. The increased potency of dimeric 2G12 over its monomeric form
in the neutralization of HIV-1 [22] was observed to also extend to its ADCC activity,
confirming the ability of Fc receptors on effector cells to bind one or both Fc regions on
dimeric 2G12. An ADCC-enhancing double mutation (Ser239 to Asp; Ile332 to Glu) that
increases the affinity of the Fc region of IgG for the activating receptor CD16 [24] yielded a
greater decrease in the EC50 value for monomeric 2G12S239D/I332E as compared to dimeric
2G12S239D/I332E in the ADCC assay. As a result, both forms of 2G12S239D/I332E showed
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similar potencies. Importantly, these ADCC-enhancing mutations did not increase non-
specific ADCC activity against target cells that did not express gp160 (Fig. 1A).
Because 2G12 dimer has twice as many Fabs and Fc regions as the monomeric form, the
6.8-fold increase in potency (i.e., 6.8-fold lower EC50 value) observed for 2G12WT dimer as
compared to 2G12WT monomer could be attributed to an increased affinity for gp160, an
increased affinity for Fc receptors on the effector cells, or both. Given that the similarity in
EC50 values observed for 2G12S239D/I332E monomer and dimer was driven mostly by the
increased potency of the monomeric form (Table 1), we conclude that the lower potency
observed for 2G12WT monomer can primarily be attributed to the weak ability of
monomeric wild-type IgG Fc regions in eliciting ADCC via CD16 engagement [24, 38].
Several lines of evidence suggest that further evaluations of the in vivo properties,
particularly the potential for eliciting ADCC, of potential anti-HIV antibodies would be
valuable. First, eliminating ADCC activity but not complement activity severely reduced the
ability of IgG b12 to protect rhesus macaques from vaginal challenge with chimeric simian/
human immunodeficiency virus (SHIV) [16]. Additional evidence is related to early events
in vaginal transmission of SIV in rhesus macaques, where it has been shown that the virus
quickly crosses the epithelial barrier to infect a small founder population of cells in the
endocervical region [39–41], and a local expansion of this founder population may be
providing a necessary supply of infected cells that migrate to the lymphatic tissues to fuel a
systemic infection (reviewed in [42]). Given the pivotal role that the founder population of
infected cells may play in establishing a productive systemic infection, containment or the
prevention of its establishment altogether represent critical opportunities for intervention in
the transmission process [42]. Unfortunately, the window of opportunity to accomplish
either of these objectives appears to be narrow: only hours for prevention after exposure and
approximately 3 days for containment [39, 40]. As NK cells are capable of mediating ADCC
without pre-stimulation by the adaptive immune system, a gene therapy that could deliver a
continuous supply of a neutralizing antibody that is also highly active in ADCC would be
well-suited to targeting both prevention and containment of the founder population.
Evidence specifically in support of the use of 2G12 as a potential therapeutic may be derived
from a comparison of the in vivo anti-viral and pharmokinetic properties of 2G12 with b12
and two other broadly neutralizing antibodies, 4E10 and 2F5. For example, studies have
shown that 2G12 can protect against challenge by SHIV in rhesus macaques at substantially
lower serum neutralizing titers than observed for b12 [17, 18, 43]. In addition, a study of
human HIV-positive subjects who were injected with a cocktail of 2G12, 4E10, and 2F5
indicated that of the three IgGs, only 2G12 exerted selective pressure against infection. In
this study, administration of the antibody cocktail resulted in a significant delay in viral
rebound after cessation of anti-retroviral therapy [25], but sequence analysis after eventual
viral rebound confirmed the emergence of escape mutations at conserved glycosylation sites
that abrogated sensitivity to 2G12, whereas no escape mutations were found to 4E10 or 2F5
[35]. The same study also found that 2G12 exhibited the longest half-life of the three
antibodies. Our current finding that 2G12 dimers retain the ability to elicit ADCC, along
with our recent finding that 2G12WT dimer exhibits significantly increased potency and
expanded cross-reactivity relative to the monomer [22], suggest that 2G12WT dimer and
2G12S239D/I332E monomer and dimer are promising candidates for use in passive
immunotherapy or prophylactic gene therapy.
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Figure 1.
ADCC and neutralization activity of 2G12. (A) Comparison of maximal lysis of target cells
expressing HXB2 trimers (CHO-gp160) and control cells (CHO-HFE) after addition of
rituximab (150 µg/mL), 2G12WT monomer (150 µg/mL), 2G12S239D/I332E monomer (150
µg/mL), 2G12WT dimer (17 µg/mL), and 2G12S239D/I332E dimer (17 µg/mL). Error bars are
the standard errors from a representative experiment conducted in triplicate. (B)
Representative neutralization assays to compare potencies of 2G12WT monomer and
2G12WT dimer against HXB2 HIV-1. Data points are the average of a triplicate
measurement ± the standard error of the mean. Average IC50 values determined from
independent neutralization assays, each conducted using triplicate measurements, are
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reported in Table 1. (C–D) Representative ADCC assays using CHO-gp160 target cells by
monomeric and dimeric 2G12WT (panel C) or monomeric and dimeric 2G12S239D/I332E
(panel D). Data points in the curves are the average of a triplicate measurement ± the
standard error of the mean. Average EC50 values determined from curves from independent
ADCC assays, each conducted using triplicate measurements, are reported in Table 1.
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Table 1
Comparison of average half-maximal effective concentrations (EC50s) in ADCC assays and half-maximal
neutralization concentrations (IC50s) in pseudovirus-based neutralization assays for monomeric and dimeric
2G12 against strain HXB2. Values are reported as the average ± the standard deviation from n independent
replicates. Bracketed values represent the average ± the standard deviation in maximal lysis. Representative
ADCC and neutralization curves are shown in Fig. 1.
EC50 (µg/mL) IC50 (µg/mL)
Form of 2G12 2G12WT 2G12S239D/I332E 2G12WT 2G12S239D/I332E
monomer
2.3 ± 0.8 0.17 ± 0.15
0.42 ± 0.11
(n = 5)
0.14
(n = 1)
(n = 6) (n = 5)a
[44 ± 27%]c [55 ± 31%]c
dimer
0.34 ± 0.22 0.051 ± 0.035
0.044 ± 0.013
(n = 5)b
0.031
(n = 1)(n = 5)
a (n = 3)a
[33 ± 9%]c [47 ± 8%]c
ap < 0.005 when compared to the average EC50 value for 2G12WT monomer.
bp < 0.0001 when compared to the average IC50 value for 2G12WT monomer.
cp > 0.05 for all pair-wise combinations.
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